- Condition: Human Immunodeficiency Virus
Interventions: Drug: Atazanavir, ritonavir, lamivudine; Drug: Atazanavir, Ritonavir, 2 NRTIs
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified May 2012 - Conditions: Varicella; Rubella; Measles; Mumps
Interventions: Biological: Priorix Tetra; Biological: Meningitec
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Certolizumab pegol
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2012 - Conditions: Acute Coronary Syndromes; STEMI; NSTEMI
Interventions: Other: trans-radial and short-term bivalirudin; Other: trans-radial and long-term bivalirudin infusion; Other: trans-radial and standard of care pharmacology; Other: Trans-femoral and Short-term bivalirudin; Other: trans-femoral and long-term bivalirudin infusion; Other: trans-femoral and standard of care pharmacology
Sponsors: Italian Society of Invasive Cardiology; Italian Society of Invasive Cardiology; Eustrategy
Recruiting - verified May 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Multiple Sclerosis; Neurodegenerative Diseases
Intervention:
Sponsors: Fondazione Italiana Sclerosi Multipla; Fondazione Italiana Sclerosi Multipla; Opera Srl
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: ALL Ph Positive
Intervention: Other: Total therapy approach
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Condition: Edentulism
Intervention: Device: OsseoSpeed TX
Sponsors: Astra Tech AB; Astra Tech AB
Recruiting - verified April 2012 - Condition: Pulmonary Fibrosis
Interventions: Drug: placebo; Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod; Drug: Interferon beta 1b
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Carotid Stenosis
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Fingoliomod; Drug: Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Nervous System Disorders
Interventions: Drug: Botulinum type A toxin (Dysport®); Drug: Placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012 - Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Glaucoma; Ocular Hypertension
Interventions: Other: No intervention other than routine medical care; Other: No intervention other than routine medical care
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide (HMR1726); Drug: Matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Leg Spasticity
Interventions: Drug: Botulinum type A toxin (Dysport®); Drug: Placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Carcinoma; Hepatocellular
Intervention: Drug: LY2157299
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: temsirolimus; Drug: temsirolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Neoplasms Malignant
Intervention: Drug: Crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673); Drug: Otamixaban matching placebo; Drug: Unfractionated Heparin; Drug: Unfractionated Heparin matching placebo; Drug: Eptifibatide; Drug: Eptifibatide matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: gemcitabine; Drug: gemcitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: bendamustine; Drug: RO5072759
Sponsors: Genentech; Genentech; Roche Pharma AG
Recruiting - verified May 2012 - Conditions: Treatment; Stem Cell Transplantation
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Conditions: Renal Transplantation; Steroids; Treatment
Interventions: Drug: everolimus, cyclosporine and steroids; Drug: everolimus, cyclosporine b.i.d. and steroid withdrawal; Drug: everolimus, cyclosporine b.i.d. and continuous steroids
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium +salmeterol+ fluticasone high dose; Drug: Tiotropium+salmeterol+ fluticasone high,med, low, placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Mantle Cell Lymphoma; Relapsed or Refractory Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide; Drug: Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hypertension, Pulmonary
Intervention: Drug: ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Leukemia, Lymphoblastic, Acute
Interventions: Procedure: Geriatric assessment adapted therapy; Procedure: Stem cells autotransplantation
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified April 2012
 |
Join Clinical Trials that are held in Catania, Italy |
Clinical Trial Locations 